caspofungin


Also found in: Wikipedia.

caspofungin

 [kas″po-fun´jin]
an antifungal used as the acetate salt in the treatment of invasive aspergillosis, administered intravenously.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

caspofungin

(kas'pō-fŭn-jin),
A member of the echinocandin class of antifungal compounds targeting the fungal cell wall.
Farlex Partner Medical Dictionary © Farlex 2012
References in periodicals archive ?
Anidulafungin and caspofungin have been approved for treatment of candidaemia and invasive candidiasis by US Food and Drug Administration (FDA).
The antifungal medication is further segmented into voriconazole, amphotericin B (AMB), itraconazole, caspofungin, echinocandins, and others.
Summary: This report on the global Caspofungin Market analyzes the current and future prospects of the market.
While the objective of STRIVE B was to show comparability in efficacy and safety of rezafungin dosed once-weekly versus caspofungin dosed once-daily, the topline results showed that patients treated with rezafungin had numerically improved outcomes compared to caspofungin across all efficacy measures at the 400 mg/200 mg dosing regimen, which is the dosing regimen chosen for Phase 3.
While the objective of STRIVE B was to show comparability in efficacy and safety of rezafungin dosed once-weekly versus caspofungin dosed once-daily, the topline results show that patients treated with rezafungin had numerically improved outcomes compared to caspofungin across all efficacy measures at the 400 mg/200 mg dosing regimen, which is the dosing regimen chosen for Phase 3.
[USPRwire, Fri Jul 12 2019] This report on the global Caspofungin Market analyzes the current and future prospects of the market.
Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.
We performed antifungal susceptibility testing for amphotericin B, fluconazole, itraconazole, voriconazole, posaconazole, caspofungin, anidulafungin, and micafungin by the microbroth dilution method recommended by the Clinical and Laboratory Standards Institute (10).
ReSTORE is a global, randomised, double-blind, controlled Phase 3 pivotal clinical trial evaluating the efficacy and safety of once-weekly intravenous dosing of rezafungin compared to once-daily dosing of caspofungin in patients with candidemia and/or invasive candidiasis.
Despite therapy with voriconazole and caspofungin, her respiratory status worsened, and therapy was switched to amphotericin B and caspofungin.